Omapatrilat

Omapatrilat is a dual inhibitor of the metalloproteases ACE and NEP with Ki values of 0.64 and 0.45 nM, respectively.

Product Specifications

CAS Number

[167305-00-2]

Product Name Alternative

BMS-186716

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Angiotensin-converting Enzyme (ACE)

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease

Applications

COVID-19-anti-virus

Field of Research

Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/Omapatrilat.html

Purity

98.87

Solubility

DMSO : ≥ 31 mg/mL

Smiles

O=C([C@@H]1CCC[C@](N21)([H])SCC[C@H](NC([C@@H](S)CC3=CC=CC=C3)=O)C2=O)O

Molecular Formula

C19H24N2O4S2

Molecular Weight

408.53

Precautions

H302, H315, H319, H335

References & Citations

[1]Fryer RM, et al. Effect of bradykinin metabolism inhibitors on evoked hypotension in rats: rank efficacy ofenzymes associated with bradykinin-mediated angioedema.Br J Pharmacol. 2008 Mar;153 (5) :947-55.|[2]Robl JA, et al. Dual metalloprotease inhibitors: mercaptoacetyl-based fused heterocyclic dipeptide mimetics asinhibitors of angiotensin-converting enzyme and neutral endopeptidase. J Med Chem. 1997 May 23;40 (11) :1570-7.|[3]Ichiki T, et al. Endothelial permeability in vitro and in vivo: protective actions of ANP and omapatrilat in experimental atherosclerosis. Peptides. 2013 Oct;48:21-6.|[4]Burrell LM, et al. Antihypertensive and antihypertrophic effects of omapatrilat in SHR. Am J Hypertens. 2000 Oct;13 (10) :1110-6.